ADCC: The Antibody Awakens…the Immune System (Part 1)

What is ADCC and why would you need it?

Antibody-dependent cell-mediated cytotoxicity (ADCC) Assay from iQ Biosciences

What is Antibody-Dependent Cell-Mediated Cytotoxicity?

Antibody-dependent cell-mediated cytotoxicity (ADCC) is the lysis of target cells mediated by antibodies that recruit effector cells to the target. This is achieved when the antigen recognition domain of the antibody binds antigen on the target, and the Fc domain of the antibody binds Fc receptors on effector cells. This engagement of Fc receptors results in activation of the effector cells and the subsequent release of cytolytic molecules towards the target to promote lysis.

What are the molecules and effector cell types involved in ADCC?

Several molecules play an important role in facilitating ADCC, including: (1) the antibody, (2) the cognate antigen, and (3) the Fc receptor. Antibodies mediate the recruitment of effector cells to target cells; therefore, this cytolytic mechanism would not proceed without antibodies. Also involved is the cognate antigen for the antibody, which has to be expressed in an abundant amount on the target cell surface. Without the antigen, the antibody cannot identify the target(s) to which to recruit the effector cell. A third component of ADCC is the activating Fc receptor, FcgRIIIa (CD16), which is present on the effector cell. Engagement of this receptor results in signaling cascades that activate the cell to secrete cytolytic molecules towards the target. These molecules include perforin and granzymes, where the former creates holes in the target while the latter are proteases that cleave molecules within the target cells.

ADCC can be mediated by a number of effector cell types. The most commonly known cell type is the Natural Killer (NK) cell, in which nearly the entire population expresses CD16. NK cells are part of the innate immune system and preloaded with cytokines and cytolytic enzymes, which are ready to be released upon cell activation. Other cell types that express CD16 include monocytes, macrophages, neutrophils, eosinophils, and dendritic cells, all of which can also mediate ADCC.

Why is ADCC important?

ADCC is very important for general human health as it eliminates foreign pathogens and aberrant cells that would otherwise promote illness. The body’s immune system will produce antibodies to coat pathogens or infected/diseased cells that express the antibody’s cognate antigen, which will subsequently recruit effector cells to trigger lysis and clearance.

Another key aspect of ADCC is its reported mechanism of action for therapeutic antibodies. It is now suggested that some therapeutic antibodies, such as Herceptin (trastuzumab), Rituxan/MabThera (Rituximab), and Campath (alemtuzumab), use ADCC with other mechanisms of action as a means to promote their effectiveness.

Furthermore, because ADCC is considered a mechanism of action for therapeutic antibodies, there have been attempts to engineer antibodies that potentiate ADCC. One successful approach has been to remove the fucose sugar on the oligosaccharide chain linked to asparagine 297. Removing fucose increases the binding affinity between the Fc portion of the antibody and CD16, which leads to stronger signaling and more effector cells being activated for ADCC. Indeed, this strategy has led to two glyco-engineered antibodies, Gazyva (obinutuzumab) and Poteligeo (mogamulizumab), currently approved on the market. Notably, Gazyva has shown better efficacy in chronic lymphocytic leukemia patients in comparison to Rituxan, suggesting that the afucosylated form of these anti-CD20 antibodies is indeed more potent.

Because findings suggest that ADCC is an important mechanism of action for therapeutic antibodies, along with attempts to engineer antibodies to potentiate ADCC, a current strategy to identify potential therapeutic antibodies is to screen for candidates that exhibit ADCC activity. Once a candidate has been identified, the antibody can be engineered to increase its potential through various methods.

Stay tuned for Part 2 of our series, “ADCC: The Antibody Awakens…the Immune System”! We’ll be discussing when ADCC assays are used and the key considerations for performing them.

Learn more about iQ Biosciences‘ expertise in performing ADCC assays.

About the Author:

Omar Duramad, Ph.D. brings more than fifteen years of experience in drug discovery and preclinical drug development for small molecules and antibodies. He oversees IQ’s In-vitro Assay Services (Testing, Safety, Toxicology, & Immunology). Prior to IQ, Dr. Duramad held positions of increasing responsibility at REGiMMUNE, IGM Biosciences, Neothera Biosciences, and Dynavax Technologies, where he led small molecule or antibody programs from early discovery through IND Filing. An immunologist by training, Dr. Duramad has received several awards such as the Schissler Foundation Fellowship in Cancer Research, American Legion Auxiliary Fellowship for Cancer Research, and the Vivian L. Smith Award for Outstanding Immunologist and has been an invited speaker at prestigious conferences such as Keystone Symposia, American Society of Hematology, and American Transplant Congress. Dr. Duramad obtained his B.S. in Biochemistry & Cell Biology from University of California, San Diego and Ph.D. in Immunology & Cancer Biology from the University of Texas, MD Anderson Cancer Center in Houston.